000286735 001__ 286735
000286735 005__ 20240301121555.0
000286735 0247_ $$2doi$$a10.3233/JAD-230961
000286735 0247_ $$2pmid$$apmid:38189757
000286735 0247_ $$2ISSN$$a1387-2877
000286735 0247_ $$2ISSN$$a1875-8908
000286735 037__ $$aDKFZ-2024-00074
000286735 041__ $$aEnglish
000286735 082__ $$a610
000286735 1001_ $$aAngelidou, Ioanna Antigoni$$b0
000286735 245__ $$aValidation of the 'Perceptions Regarding pRE-Symptomatic Alzheimer's Disease Screening' (PRE-ADS) Questionnaire in the German Population: Attitudes, Motivations, and Barriers to Pre-Symptomatic Dementia Screening.
000286735 260__ $$aAmsterdam$$bIOS Press$$c2024
000286735 3367_ $$2DRIVER$$aarticle
000286735 3367_ $$2DataCite$$aOutput Types/Journal article
000286735 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1704812495_20277
000286735 3367_ $$2BibTeX$$aARTICLE
000286735 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000286735 3367_ $$00$$2EndNote$$aJournal Article
000286735 520__ $$aAttitudes, motivations, and barriers to pre-symptomatic screening for Alzheimer's disease (AD) in the general population are unclear, and validated measurement tools are lacking.Translation and validation of the German version of the 'Perceptions regarding pRE-symptomatic Alzheimer's Disease Screening' (PRE-ADS) questionnaire.A convenience sample (N = 256) was recruited via an online platform. Validation of the PRE-ADS-D consisted of assessments of reliability, structural validity using Principal Component Analysis (PCA) and Exploratory Factor Analysis (EFA) and construct validity using known-group tests. A subscale 'Acceptability of Screening', with 5 PRE-ADS-D items, was extracted to measure acceptance of screening in clinical practice. The STROBE checklist was used for reporting.EFA revealed a three-factor model for the PRE-ADS-D. Acceptable to good internal consistency was found for the 25-item scale (α= 0.78), as well as for the three factors 'Concerns about Screening' (α= 0.85), 'Intention to be Screened' (α= 0.87), and 'Preventive Health Behaviors' (α= 0.81). Construct validity was confirmed for both the 25-item PRE-ADS-D and the 'Acceptability of Screening' scale (α= 0.91). Overall, 51.2% of the participants showed a preference for screening. Non-parametric tests were conducted to further explore group differences of the sample.The PRE-ADS-D is a reliable and valid tool to measure attitudes, motives, and barriers regarding pre-symptomatic dementia screening in the German-speaking general population. Additionally, the subscale 'Acceptability of Screening' demonstrated good construct validity and reliability, suggesting its promising potential as a practical tool in clinical practice.
000286735 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000286735 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000286735 650_7 $$2Other$$aAlzheimer’s disease
000286735 650_7 $$2Other$$aattitude
000286735 650_7 $$2Other$$abiomarker
000286735 650_7 $$2Other$$apsychometrics
000286735 650_7 $$2Other$$ascreening
000286735 650_7 $$2Other$$avalidity
000286735 650_2 $$2MeSH$$aHumans
000286735 650_2 $$2MeSH$$aMotivation
000286735 650_2 $$2MeSH$$aAlzheimer Disease: diagnosis
000286735 650_2 $$2MeSH$$aReproducibility of Results
000286735 650_2 $$2MeSH$$aAsymptomatic Diseases
000286735 650_2 $$2MeSH$$aChecklist
000286735 7001_ $$0P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aStocker, Hannah$$b1$$udkfz
000286735 7001_ $$aBeyreuther, Konrad$$b2
000286735 7001_ $$aTeichmann, Birgit$$b3
000286735 773__ $$0PERI:(DE-600)2070772-1$$a10.3233/JAD-230961$$gVol. 97, no. 1, p. 309 - 325$$n1$$p309 - 325$$tJournal of Alzheimer's disease$$v97$$x1387-2877$$y2024
000286735 909CO $$ooai:inrepo02.dkfz.de:286735$$pVDB
000286735 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)104fae0755c89365b7ae32238b3f1f52$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000286735 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000286735 9141_ $$y2024
000286735 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ ALZHEIMERS DIS : 2022$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-25
000286735 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2023-08-25
000286735 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000286735 980__ $$ajournal
000286735 980__ $$aVDB
000286735 980__ $$aI:(DE-He78)C070-20160331
000286735 980__ $$aUNRESTRICTED